ATI RN
ATI Pharmacology Quizlet
1. A client is receiving treatment with etoposide. Which of the following findings should the nurse monitor?
- A. Hypotension
- B. Hyperkalemia
- C. Hyperglycemia
- D. Hypertension
Correct answer: A
Rationale: Etoposide, a chemotherapeutic agent, commonly causes hypotension as an adverse effect. It is crucial for the nurse to monitor the client for signs of hypotension, such as dizziness, lightheadedness, or a drop in blood pressure, to promptly intervene and prevent complications.
2. A healthcare provider is teaching a client who has a new prescription for Bisacodyl suppositories. Which of the following information should the provider include?
- A. Expect results within 15 to 60 minutes.
- B. Insert the suppository as directed by the healthcare provider.
- C. Keep the suppository at room temperature.
- D. Expect rectal burning.
Correct answer: D
Rationale: When educating a client about Bisacodyl suppositories, it is important to include information about the common side effects. Rectal burning is a frequent side effect that can occur after using Bisacodyl suppositories, so the client should be informed to expect this discomfort. The onset of action for Bisacodyl suppositories is typically within 15 to 60 minutes, so the client should expect results relatively quickly, not in 6 to 12 hours. It is essential to follow the healthcare provider's instructions on how to insert the suppository correctly. Keeping the suppository at room temperature is sufficient; refrigeration is not required. Therefore, option D is the correct choice as it addresses a common side effect and prepares the client for potential discomfort. Options A, B, and C are incorrect as they do not focus on a significant side effect, proper administration, or storage requirements.
3. A client in the operating room received a dose of Succinylcholine. During the operation, the client suddenly develops rigidity, and their body temperature begins to rise. The healthcare provider should anticipate a prescription for which of the following medications?
- A. Neostigmine
- B. Naloxone
- C. Dantrolene
- D. Vecuronium
Correct answer: C
Rationale: Muscle rigidity and a sudden rise in temperature are manifestations of malignant hyperthermia. Dantrolene acts on skeletal muscles to reduce metabolic activity and treat malignant hyperthermia effectively. Neostigmine (choice A) is used to reverse the effects of non-depolarizing neuromuscular blockers, not to treat malignant hyperthermia. Naloxone (choice B) is an opioid antagonist used for opioid overdose. Vecuronium (choice D) is a non-depolarizing neuromuscular blocker and is not used to treat malignant hyperthermia.
4. A client in a substance abuse clinic is being assessed by a nurse after discontinuing disulfiram due to severe nausea and vomiting. What is the likely cause of the client's distress?
- A. The client demonstrated an allergic response to the medication.
- B. The client experienced a common side effect of the medication.
- C. The client consumed alcohol while taking the medication.
- D. The client took an overdose of the medication.
Correct answer: C
Rationale: Disulfiram, when combined with alcohol, leads to a severe reaction causing nausea and vomiting. Since the client experienced these symptoms after starting disulfiram, it is likely that they consumed alcohol while taking the medication. Choice A is incorrect because the symptoms are more indicative of the interaction with alcohol rather than an allergic response. Choice B is incorrect as severe nausea and vomiting are not common side effects of disulfiram alone. Choice D is incorrect as there is no indication of an overdose based on the symptoms described.
5. A client is receiving treatment with bevacizumab. Which of the following findings should the nurse monitor?
- A. Hypertension
- B. Hypokalemia
- C. Hyperglycemia
- D. Hypocalcemia
Correct answer: A
Rationale: Corrected Rationale: Bevacizumab is known to potentially cause hypertension as a common adverse effect. The nurse should monitor the client's blood pressure regularly to detect and manage any elevations effectively. Choices B, C, and D are incorrect because bevacizumab is not typically associated with causing hypokalemia, hyperglycemia, or hypocalcemia. Therefore, monitoring for hypertension is the priority in this case.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access